8.8587

1.26% 0.0987

Regenxbio Inc (RGNX)

Overview News Price History Option Chain Financials Discussions Forecast

Regenxbio Inc stock is traded at $8.8587, with a volume of 157.40K. It is up +1.26% in the last 24 hours and down -8.74% over the past month. Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.

Previous Close:

$8.76

Open:

$8.7

24h Volume:

157.40K

Relative Volume:

0.34

Market Cap:

$443.33M

Revenue:

$89.04M

Net Income/Loss:

$-241.08M

P/E Ratio:

-1.4017

EPS:

-6.32

Net Cash Flow:

$-194.72M

1W Performance:

-2.10%

1M Performance:

-8.74%

6M Performance:

-47.30%

1Y Performance:

-42.14%

1-Day Range:

$8.58

$8.97

1-Week Range:

$8.535

$9.27

52-Week Range:

$8.535

$28.80

Regenxbio Inc Stock (RGNX) Company Profile

Name

Regenxbio Inc

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

240-552-8181

Address

9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD

Employee

344

Twitter

@REGENXBIO

Next Earnings Date

2024-11-06

Latest SEC Filings

RGNX's Discussions on Twitter

Regenxbio Inc Stock (RGNX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-01-23	Initiated	Stifel	Buy
Jun-02-23	Initiated	Robert W. Baird	Outperform
Jun-23-22	Initiated	Berenberg	Buy
Dec-15-21	Initiated	Wedbush	Neutral
Oct-19-21	Resumed	Morgan Stanley	Overweight
Jan-06-21	Upgrade	Raymond James	Outperform → Strong Buy
Dec-16-20	Initiated	UBS	Buy
Jun-25-20	Resumed	BofA/Merrill	Buy
May-13-20	Initiated	RBC Capital Mkts	Sector Perform
Aug-20-19	Upgrade	SVB Leerink	Underperform → Mkt Perform
Jun-18-19	Reiterated	Chardan Capital Markets	Buy
Jun-14-19	Resumed	Raymond James	Outperform
Jun-05-19	Reiterated	Chardan Capital Markets	Buy
Feb-25-19	Upgrade	Evercore ISI	In-line → Outperform
Feb-05-19	Upgrade	Raymond James	Outperform → Strong Buy
Dec-17-18	Reiterated	Chardan Capital Markets	Buy
Nov-08-18	Reiterated	BofA/Merrill	Neutral
Aug-08-18	Reiterated	Chardan Capital Markets	Buy
Jul-23-18	Downgrade	BofA/Merrill	Buy → Neutral
Jul-10-18	Reiterated	Chardan Capital Markets	Buy
May-09-18	Reiterated	Barclays	Overweight
Apr-09-18	Reiterated	Chardan Capital Markets	Buy
Mar-12-18	Downgrade	Evercore ISI	Outperform → In-line
Feb-13-18	Initiated	Mizuho	Neutral
Nov-09-17	Resumed	Morgan Stanley	Overweight

View All

Regenxbio Inc Stock (RGNX) Latest News

01:51 AM

Sorrento Therapeutics (OTCMKTS:SRNEQ) & REGENXBIO (NASDAQ:RGNX) Financial Survey - Defense World

01:51 AM

Nov 04, 2024

REGENXBIO to Participate in Upcoming Investor Conferences - StockTitan

Nov 04, 2024

Nov 03, 2024

When (RGNX) Moves Investors should Listen - Stock Traders Daily

Nov 03, 2024

Oct 31, 2024

REGENXBIO: With Additional MPS II Data, Program Advancement Remains On Track (NASDAQ:RGNX) - Seeking Alpha

Oct 31, 2024

REGENXBIO (RGNX) to Release Quarterly Earnings on Wednesday - MarketBeat

Oct 31, 2024

Oct 30, 2024

REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2024 Financial Results and Recent Operational Highlights - StockTitan

Oct 30, 2024

Assenagon Asset Management S.A. Lowers Position in REGENXBIO Inc. (NASDAQ:RGNX) - MarketBeat

Oct 30, 2024

Oct 29, 2024

RGNX stock touches 52-week low at $9.1 amid market challenges By Investing.com - Investing.com South Africa

Oct 29, 2024

RGNX stock touches 52-week low at $9.1 amid market challenges - Investing.com

Oct 29, 2024

Oct 26, 2024

SG Americas Securities LLC Makes New Investment in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World

Oct 26, 2024

Oct 24, 2024

How the (RGNX) price action is used to our Advantage - Stock Traders Daily

Oct 24, 2024

REGENXBIO (NASDAQ:RGNX) Rating Reiterated by Chardan Capital - Defense World

Oct 24, 2024

Oct 23, 2024

The past five years for REGENXBIO (NASDAQ:RGNX) investors has not been profitable - Yahoo Finance

Oct 23, 2024

REGENXBIO Inc. (NASDAQ:RGNX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat

Oct 23, 2024

Oct 22, 2024

REGENXBIO (NASDAQ:RGNX) Earns Buy Rating from Chardan Capital - MarketBeat

Oct 22, 2024

REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting - Citizentribune

Oct 22, 2024

Oct 21, 2024

REGENXBIO (NASDAQ:RGNX) Trading Down 6.4%Time to Sell? - MarketBeat

Oct 21, 2024

REGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024 - Citizentribune

Oct 21, 2024

ABBV-RGX-314 shows promise in wet AMD treatment By Investing.com - Investing.com UK

Oct 21, 2024

Oct 17, 2024

JPMorgan Chase & Co. Reduces Stake in Regenxbio Inc - Yahoo Finance

Oct 17, 2024

Investors in REGENXBIO (NASDAQ:RGNX) from five years ago are still down 72%, even after 16% gain this past week - Simply Wall St

Oct 17, 2024

Oct 16, 2024

REGENXBIO (NASDAQ:RGNX) Stock Price Up 6.6%Should You Buy? - MarketBeat

Oct 16, 2024

Oct 14, 2024